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Abstract
Background: Several proteins are known to be markedly expressed in the brain during cerebral ischemia; however,
the changes in protein profiles within the ischemic brain after an ischemic insult have not been fully elucidated.
We studied the changes in the ischemic brain proteome after focal cerebral ischemia, induced by middle cerebral
artery occlusion (MCAO) in mice.
Methods: LCMS-IT-TOF mass spectrometry was used to detect the changes in ischemic brain protein patterns after
MCAO. We evaluated the protein expression detected in the ischemic area, by western blotting and
immunohistochemistry.
Results: Nine unique proteins were identified from the ischemic area at 10 h after ischemic insult. Among these
proteins, we focused on Rab33b, a member of RAS oncogene family and we found that Rab33b was up-regulated
in the ischemic striatum and the number of Rab33B-positive cells increased in a time-dependent manner. Rab33B
colocalized with Iba-1 positive microglia in the ischemic area.
Conclusion: These findings suggest that LCMS-IT-TOF is useful for identifying changes in proteins after cerebral
ischemia and that Rab33B is partially related to the pathogenesis of transient cerebral ischemia in mice.
Background
Stroke is the third most common cause of death, after
heart attack and cancer, and it has profound negative
social and economic effects. The current treatment for
complete stroke is only partially successful at reversing
neurodegeneration and restoring premorbid function.
Since stroke is one of the principal etiologies for neurolo-
gical sequelae and/or death, it is very important to under-
stand both its pathologic mechanisms and any effective
treatments. Understanding the cellular mechanisms of
ischemia-reperfusion injury is of great importance for
stroke therapy; however, the precise mechanisms still
remain unclear. The identification and characterization
o ft h ei s c h e m i ca r e aa r ev a l u a b l ea n du s e f u lf o ru n d e r -
standing the pathogenesis and for establishing new thera-
peutic strategies to treat or prevent brain ischemia.
Proteome analysis, an exhaustive analytical technique
for analyzing proteins, is primarily conducted using
ESI-LCMS or MALDI-TOFMS. Many proteins and pep-
tides are extremely minute in quantity, requiring the
enhanced sensitivity provided by mass spectrometers.
Shimadzu’s new LCMS-IT-TOF is a novel hybrid mass
spectrometer that is applicable to a wide range of bioa-
nalytical research, including biomarker discovery, meta-
bolite identification, and drug development, among
others. Coupling atmospheric pressure ionization with
Ion-Trap (IT) and Time-of-Flight (TOF) technologies,
the LCMS-IT-TOF delivers high mass accuracy and
high mass resolution (10,000 at 1000 m/z) independent
of MS mode. The LCMS-IT-TOF allows more qualita-
tive information about a sample to be collected in a sin-
gle run. This enables researchers and scientists to: 1.
elucidate structures of new molecules; 2. identify impu-
rities and contaminants; and 3. analyze metabolites and
biomarkers to evaluate biological pathways. The LCMS-
IT-TOF has been designed to maximize sensitivity and
selectivity by optimizing the ion transport to the TOF
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pole ion trap. The ion trap is used to focus ions prior to
ejection into the TOF as well as to support MS
n analysis
with effective precursor ion selection capabilities (reso-
lution > 1,000 at 1,000 m/z).
The quest for biological markers of disease is a chal-
lenge for investigators in many fields, and this is certainly
the case in the study of neurologic disease. One of the
goals of proteomics is to characterize cellular proteins,
secreted proteins and peptides, and proteolytic fragments
for use as potential biomarkers. The objective of the pre-
sent study was to identify ischemia-related proteins using
the new LCMS-IT-TOF to analyze the chronological
change of protein peaks following ischemia/reperfusion.
Methods
Animals
The experimental designs and all procedures were in
accordance with the U.S. National Institutes of Health
G u i d ef o rt h eC a r ea n dU s eo fL a b o r a t o r yA n i m a l sa n d
Animal Care Guidelines issued by the Animal Experi-
mental Committee of Gifu Pharmaceutical University.
All experiments were performed using male ddY mice
(4-5 weeks old, Japan SLC, Ltd., Shizuoka, Japan). Every
effort was made to minimize the number of animals
used and their suffering.
Drugs
Formic acid (HCOOH) and trifluoroacetic acid (TFA)
were purchased form Wako pure chemical (Osaka,
Japan). HPLC-grade ACN (CH3CN) and water were
also obtained from Wako pure chemical. A Liquid
Tissue MS Protein Kit was obtained from Expression
Pathology Inc. (Gaithersburug, MD, USA). Pentobarbital
sodium and isoflurane were purchased from Nissan
Kagaku (Tokyo, Japan) and Merck Hoei Ltd. (Osaka,
Japan), respectively.
Focal cerebral ischemia model in mice
Anesthesia was induced using 2.0 to 3.0% isoflurane and
maintained using 1.0 to 1.5% isoflurane (both in 70%
N2O/30% O2) by means of an animal general anesthesia
machine (Soft Lander; Sin-ei Industry Co. Ltd., Saitama,
Japan). Body temperature was maintained at 37.0 to
37.5°C with the aid of a heating pad and heating lamp.
After a midline skin incision, the left external carotid
artery was exposed, and its branches were occluded
[1,2]. An 8-0 nylon monofilament (Ethicon, Somerville,
NJ, USA) coated with a mixture of silicone resin (Xan-
topren; Bayer Dental, Osaka, Japan) was introduced into
the left internal carotid artery through the external caro-
tid artery stump so as to occlude the origin of the mid-
dle cerebral artery. Then, the left common carotid
artery was occluded. After 2 h of occlusion, the animal
was reanesthetized briefly and reperfusion initiated via
withdrawal of the monofilament. After surgery, the mice
were kept in the preoperative condition (24 ± 2°C) until
sampling. To confirm the induction of MCAO, a laser-
Doppler flowmetry (Omegaflow flo-N1; Omegawave
Inc., Tokyo, Japan) measured the regional artery blood
flow (rCBF) in the MCA territory from the temporal
bone surface. Mice that did not demonstrate a signifi-
cant reduction just before reperfusion (to less than 40%
that of the contralateral rCBF values) were excluded.
Tissue micro dissection
The left ventricle was perfused with 4% paraformalde-
hyde in 0.1 M phosphate buffer (PB; pH 7.4). Brains
were removed after 15 min perfusion fixation at 4°C,
then immersed in the same fixative solution overnight
at 4°C. They were then immersed in 25% sucrose in 0.1
M PB for 24 h, and finally frozen in liquid nitrogen.
Coronal sections (14 μm thick) were cut on a cryostat at
-20°C, and the ischemic core area and a non-ischemic
area (2 mm × 2 mm) were excised and placed in clear
1.5 ml tubes.
Protein Extraction
Micro dissected specimens were processed by reagents
according to the manufacturer’sr e c o m m e n d a t i o n s
(Expression Pathology Inc., Rockville, MD, USA). Briefly,
material was suspended in 20 μl of reaction buffer, incu-
bated at 95°C for 90 min, then cooled on ice for 2 min,
at which time 1 μl of trypsin was added followed by
incubation at 37°C for 18 h. Dithiothreitol was added to
a final concentration of 10 mM, and the sample were
heated for 5 min at 95°C to reduce cysteine residues.
Finally, Liquid Tissue MS Protein Kit extracts were
desalted with C-18 Zip Tip microcolumns (Millipore,
Bedford, MA, USA), lyophilized, and resuspended in a
minimal amount of 0.1% formic acid in 2% ACN.
NanoRPLC-MS/MS Analysis
NanoRPLC was performed using a DiNa-2A nanoLC
system (KYA Technologies, Tokyo, Japan) coupled
o n l i n et oaL C M S - I T - T O F( S h i m a d z u ,K y o t o ,J a p a n ) .
NanoRPLC separation was performed using a Pico Frit
Beta Basic C18 column (New Objective, Woburn, MA,
USA) at a constant flow rate of 300 nl/min. After injec-
tion of 1 μl of sample, peptides were eluted using gradi-
ents of 5-40% solvent B (0.1% formic acid in 80%
ACN)/0-30 min, 40-100% solvent B/30-40 min, and
100-100% solvent B/40-60 min. LCMS-IT-TOF was
operated in the data-dependent MS/MS mode. The
heated capillary temperature and electrospray voltage
were set at 200°C and 2.3KV, respectively. Data were
collected at scan ranges of 400-1500 for MS and
50-1500 for MS/MS.
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MS/MS spectra were searched against the NCBI data-
base using Mascot (Matrix Science Ltd, London, UK)
with a peptide mass tolerance of ± 0.05 Da and a frag-
ment mass tolerance of ± 0.05 Da.
Western blotting
Mice were deeply anesthetized and decapitated at 8 h
after reperfusion (Figure 1), brains were quickly removed,
and the left hemispheres were cut into 3 mm coronal sec-
tions (between 4 and 7 mm from the frontal forebrain).
Brain samples were divided into cortex and striatum and
each sample was homogenized in 10 ml/g tissue ice-cold
lysis buffer [50 mM Tris-HCl (pH8.0) containing 150
mM NaCl, 50 mM EDTA, 1% Triton X-100, and pro-
tease/phosphatase inhibitor mixture] and centrifuged at
14,000 × g for 40 min at 4°C. An aliquot of 5 μgo fp r o -
tein was subjected to 10% sodium dodecyl sulfate-polya-
crylamide gel electrophoresis and then separated proteins
were transferred onto a polyvinylidene difluoride mem-
brane. For immunoblotting, the following primary anti-
bodies were used: mouse anti-Rab33B monoclonal
antibody (1 μg/mL: Frontier Science, Hokkaido, Japan),
monoclonal anti-b-actin (1:1000 dilution: Sigma-Aldrich
C o . ,S t .L o u i s ,M O ,U S A ) .T he secondary antibody was
anti-mouse HRP-conjugated IgG (1:2000 dilution, Pierce
Biotechnology, Rockford, IL, USA). The immunoreactive
bands were visualized using SuperSignal West Femto
maximum sensitivity substrate (Pierce Biotechnology).
The band intensity was measured using a Lumino ima-
ging analyzer (LAS-4000: Fuji Film, Tokyo, Japan).
Immunohistochemistry
At 1, 3, 6, and 10 h after the 2 h ischemia-reperfusion
treatment (Figure 1), mice were injected with sodium
pentobarbital (Nembutal; 50 mg/kg, i.p.), then perfused
through the left ventricle with 4% paraformaldehyde in
0.1 M phosphate buffer (PB; pH 7.4). Brains were
removed after 15 min perfusion fixation at 4°C, then
immersed in the same fixative solution overnight at 4°C.
They were then immersed in 25% sucrose in 0.1 M PB
for 24 h, and finally frozen in liquid nitrogen. Coronal
sections (14 μmt h i c k )w e r ec u to nac r y o s t a ta t- 2 0 ° C
and stored at -80°C until use.
Sections were rinsed three times in PBS, incubated in
3% H2O2 in PBS for 30 min, then placed in PBS and
blocked with 1% mouse serum for 30 min. A mouse
monoclonal antibody against Rab33b (3 μg/mL: Frontier
Science) was applied to sections overnight at 4°C. Sec-
ondary antibody (M.O.M. biotinylated anti-mouse) was
applied for 10 min. The avidin/biotinylated horseradish
peroxidase complex (ABC Elite kit; Vector Laboratories,
Burlingame, CA, USA) was applied for 30 min, and the
sections were allowed to develop the chromogen in
3,3-diaminobenzidine nickel solution for 2 min. Rab33B-
stained cells were counted in the ischemic area.
Double-immunostaining
For immunohistochemistry, mice were anesthetized with
sodium pentobarbital and their brains were perfused
with 4% paraformaldehyde at 8 h after the 2 h ischemia-
reperfusion treatment (Figure 1). The perfused brains
were dissected out, fixed in 4% paraformaldehyde for
overnight, and frozen. Coronal brain sections (14 μm)
were cut on a cryostat. For immunofluorescent double
staining, sections were incubated overnight at 4°C with
the primary antibodies: anti-Rab33B antibody (3 μg/mL:
Frontier science), or anti- Iba-1 antibody (1:500 dilution:
Wako pure chemical). Then, they were incubated for
3 h with Alexa Fluor 488 F (ab’)2 fragment of goat anti-
rabbit IgG (H+L) antibody, Alexa Fluor 546 F (ab’)2
fragment of goat anti-mouse IgG (H+L) antibody.
Figure 1 Protocol of all experiments. The sampling time are mentioned. See in method section.
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To quantify Rab33B-positive cells after ischemia-
reperfusion, the number of Rab33B-positive cells in the
ischemic striatum; two areas, the superior and inferior
areas were counted in a high-power field (×200) ran-
d o m l yc h o s e ni nas e c t i o nt h r o u g ht h ea n t e r i o r
commissure.
Statistical analysis
Data are presented as the means ± S.E.M. Statistical
comparison were made using a one-way ANOVA fol-
lowed by Student’s t-test or Dunett’s test using Statview
version 5.0 (SAS Institute Inc., Cary, NC, USA), with p
< 0.05 considered statistically significant.
Results
NanoRPLC-MS/MS Analysis
In the control group, 27 proteins were identified from
NanoRPLC-MS/MS analysis (Figure 2A and 2B). In an
ischemia group at 8 h after 2 h ischemia-reperfusion
(Figure 1), NanoRPLC-MS/MS analysis etected 18 pro-
teins from the ischemic area (Figure 2B and 2C). From
the NanoRPLC-MS/MS analysis, we identified nine
unique proteins that were detected only in the ischemic
area (Figure 2C).
Western blotting for Rab33B
Of these nine unique proteins (Figure 2C), we focused
on RAB33B, a member of the RAS oncogene family.
First, we examined whether Rab33B was up-regulated in
an ischemic group by western blotting. Rab33B was
increased in the ischemic striatum, but not in the
ischemic cortex (Figure 3A). In quantitative analysis,
Rab33B was present at significantly greater levels in the
ischemic striatum than in the control striatum (Figure
3B), but no difference was noted between the ischemic
cortex and the control cortex (Figure 3C).
Expression of Rab33B after ischemia
Next, we investigated changes in Rab33B expressions at 1,
3, 6, and 10 h after reperfusion by immunohistochemical
analysis (Figure 4B). Quantitative analyses of Rab33B-posi-
tive cells are shown in Figure 4C. In the ischemic area, the
number of Rab33B-positive cells was increased in a time-
d e p e n d e n tm a n n e rf r o m1ht o1 0hf o l l o w i n gt h e2h
ischemia-reperfusion treatment. No Rab33B-positive cells
were detected in non-ischemic areas.
Localization of Rab33B after ischemia
To identify Rab33B-positive cells, double immunofluores-
cence was performed for Rab33B and Iba-1 which is the
marker of activated microlgia at 8 h after the 2 h ische-
mia-reperfusion. Iba-1-Positive microglias were
expressed with Rab33b together in ischemic striatum
(Figure 5B-b), but not in non-ischemic area (Figure 5B-a).
Discussion
In the present study, we identified ischemia-related pro-
teins using an LCMS-IT-TOF to analyze the chronological
changes in protein peaks following ischemia/reperfusion
Figure 2 Proteins identified with NanoRPLC-MS/MS Analysis. (A) 18 proteins identified from control group only. (B) 9 proteins identified
from both control and ischemia group. (C) 9 proteins identified from ischemia group only.
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ment which is able to detect the candidates of the protein
markers for cerebral ischemia. For analyzing the peptides
by LCMS, peptides which were obtained by extracting
proteins from tissue samples and trypsin digestion were
used. There are differences between control and ischemia
brain groups in the amount of protein and peptide. And
the LCMS detects from the peptide fragments in decreas-
ing order. In the present study, beta-actin of house-
keeping gene was detected in only ischemia group due to
their differences. The beta-actin was expressed in both
ischemia group and control groups, and the expression
Figure 3 Western blot analysis of Rab33B in ischemic area at 8 h after 2 h ischemia -reperfusion. (A) Representative band image showed
Rab33B expression of ischemia (I) group and control (C) group. (B) and (C) Rab33B expressions were quantified by densitometry and corrected
by reference to b-actin. (* P < 0.05, t-test) Data are shown as mean ± S.E.M. (n = 4 or 5).
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Page 5 of 9Figure 4 Change in levels of Rab33B expression in the ischemic area after 2 h ischemia-reperfusion. (A) Schematic drawing showing
brain regions at 0.4-1.0 mm anterior to bregma (through the anterior commissure). (B) Immunostaining for Rab33B at 1 h, 3 h, 6 h, and 10 h
after reperfusion in mice. Scale bar = 50 μm. (C) The number of Rab33B-positive cells in the ischemic striatum. Values are shown the number of
Rab33B-positive cells/mm
2. Data are shown as mean ± S.E.M. (n = 4). ** P < 0.01 vs. control (Dunnett’s test).
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beta-actin may play a role as a house-keeping gene in the
present study.
We found an up-regulation of nine unique proteins
i nt h ei s c h e m i cb r a i na r e a s .Among these proteins, we
identified three Rab proteins. In the Rab family, the
past reports concerning Rab33B were few and its func-
tion is not well known. Therefore, we focused on
Rab33B in the present study. The Rab family of pro-
teins is a member of the Ras superfamily of monomeric
G proteins [3]. At least 60 Rab genes are found in the
human genome and are widely distributed over the
human chromosomes [4]. Rab GTPases have emerged
as central regulators of vesicle budding, motility, and
fusion and a number of these proteins are conserved
from yeast to humans. Like other regulatory GTPases,
the Rab proteins switch between two distinct confor-
mations, one GTP-bound and the other GDP-bound.
The GTP-bound conformation is generally regarded as
the ‘active’ form, as it is the one that interacts with
downstream effector proteins [5,6].
In the present study, we focused on Rab33B, which
was identified in ischemic areas by proteome analysis.
Rab33B is one of two members of the Rab33 subfamily.
In contrast to its neural and immune cell homolog,
Rab33B is ubiquitously expressed in mammalian tissues
and is localized to the medial golgi [7]. Rab33B has been
described as a Golgi-resident protein which is involved
in Golgi-to-endoplasmic reticulum transport and in
modulation of autophagy [8-10].
Figure 5 Localization of Rab33B in ischemic area. (A) Schematic drawing showing brain regions at 0.4-1.0 mm anterior to bregma (through
the anterior commissure): Measurement areas (a and b) in figure 5A in the contralateral non-ischemic and ischemic core, respectively. (B)
Double-immunostaining of Rab33B and Iba-1. Rab33B expressed in microglia at 8 h after the ischemia reperfusion. (a) contralateral side (non-
ischemic area). (b) ipsilateral side (ischemic area). Scale bar = 20 μm.
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in response to cell stress. It is a phenomenon in which
the cytoplasmic organelles in the cell are engulfed by
double membrane vesicles, the autophagosomes, and are
delivered to the lysosomes. There, the organelle proteins
are broken down by lysosomal proteases and the result-
ing amino acids are recycled back into the cell machin-
ery to aid in cell survival [11,12]. A number of key
autophagy (Atg) proteins are apparently involved in this
process [10,13]. Rab33B directly interacts with one of
these, Atg16L, in a GTP-dependent manner. Therefore,
activation and inactivation of Rab33B can modulate
autophagy [7,8]. Autophagy appears to be a vital event
in the development of the central nervous system
[14,15] and is also constitutively active in healthy neu-
rons, where it aids in survival [16].
In the present study, we examined whether Rab33B
colocalized with LC3 of autophagy marker. However, we
could not detect the expression of LC3 in ischemic area
at 8 h after 2 h ischemia-reperfusion (data not shown).
It is reported that the autophagy was detected in
ischemic area with a peak at 1 day after the transient
MCAO [17]. In the present study, we focused on the
expressions of the ischemia related proteins at early
phase after ischemia-reperfusion. Further studies are
needed to clarify the involvement of Rab33B to autop-
hagy after cerebral ischemia, especially later phase than
the present study.
Microglia, which is one of the glial cells, is approxi-
mately 20% of the total glial cell population within the
brain. Unlike astrocyte, individual microglias are distrib-
uted in large non-overlapping regions throughout the
brain and spinal cord [18]. Activation of microglia com-
monly occurs in the early response of the CNS to a
wide variety of pathological stimuli, such as neurological
degeneration, inflammation, and ischemia [19-21]. It is
unclear that microglias are necessarily damaged follow-
ing brain ischemia, but recent evidences suggest that
activated microglia may contribute to the injury. Some
neuroprotective drugs, such as minocycline and edra-
vone, improved the stroke outcomes by inhibiting the
microglial activation [22-24]. Microglia exerts a cyto-
toxic function by releasing reactive oxygen species, nitric
oxide, and inflammatory cytokines, which trigger the
neuronal damage [25-27]. Several studies have suggested
that microglia may be rapidly and time-dependently
activated after ischemia, and the microglial activation
may reflect the extent of severity of ischemic injury. In
the present study, an up-regulation and a time-depen-
dent increase in Rab33B was observed in ischemic stria-
tum (primarily in the ischemic core area) and was
colocalized with Iba-1 positive activated microglia.
Taken together, Rab33B may contribute to the neuronal
cell death in the ischemic core area.
Conclusions
These findings suggest that Rab33B is involved in the
mechanism of pathogenesis of transient cerebral ische-
mia in mice and that it may be contribute to the neuro-
nal cell death. Thus, control of the Rab33B gene and/or
protein after ischemia may prove to be a useful strategy
for therapeutic treatment of ischemic stroke. Further
studies are needed to clarify the function of Rab33B in
cerebral ischemia.
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